NAS:NBSE (USA) Also Trade In: Germany

NeuBase Therapeutics Inc $ 7.6 -0.2 (-2.56%)

Volume:
210,549
Avg Vol (1m):
210,925
Market Cap $:
175.73 Mil
Enterprise Value $:
140.13 Mil
P/E (TTM):
0.00
P/B:
5.07
Warning! GuruFocus has detected 2 Severe warning signs with NBSE. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for NeuBase Therapeutics Inc () from 2004 to Sep 28 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. NeuBase Therapeutics stock (NBSE) PE ratio as of Sep 28 2020 is 0. More Details

NeuBase Therapeutics PE Ratio (TTM) Chart

EMBED

NeuBase Therapeutics PE Ratio (TTM) Historical Data

Total 1307
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
NeuBase Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2020-09-280.0 2020-07-270.0
2020-09-250.0 2020-07-240.0
2020-09-240.0 2020-07-230.0
2020-09-230.0 2020-07-220.0
2020-09-220.0 2020-07-210.0
2020-09-210.0 2020-07-200.0
2020-09-180.0 2020-07-170.0
2020-09-170.0 2020-07-160.0
2020-09-160.0 2020-07-150.0
2020-09-150.0 2020-07-140.0
2020-09-140.0 2020-07-130.0
2020-09-110.0 2020-07-100.0
2020-09-100.0 2020-07-090.0
2020-09-090.0 2020-07-080.0
2020-09-080.0 2020-07-070.0
2020-09-070.0 2020-07-060.0
2020-09-040.0 2020-07-030.0
2020-09-030.0 2020-07-020.0
2020-09-020.0 2020-07-010.0
2020-09-010.0 2020-06-300.0
2020-08-310.0 2020-06-290.0
2020-08-280.0 2020-06-260.0
2020-08-270.0 2020-06-250.0
2020-08-260.0 2020-06-240.0
2020-08-250.0 2020-06-230.0
2020-08-240.0 2020-06-220.0
2020-08-210.0 2020-06-190.0
2020-08-200.0 2020-06-180.0
2020-08-190.0 2020-06-170.0
2020-08-180.0 2020-06-160.0
2020-08-170.0 2020-06-150.0
2020-08-140.0 2020-06-120.0
2020-08-130.0 2020-06-110.0
2020-08-120.0 2020-06-100.0
2020-08-110.0 2020-06-090.0
2020-08-100.0 2020-06-080.0
2020-08-070.0 2020-06-050.0
2020-08-060.0 2020-06-040.0
2020-08-050.0 2020-06-030.0
2020-08-040.0 2020-06-020.0
2020-08-030.0 2020-06-010.0
2020-07-310.0 2020-05-290.0
2020-07-300.0 2020-05-280.0
2020-07-290.0 2020-05-270.0
2020-07-280.0 2020-05-260.0

NeuBase Therapeutics PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325412 NAICS : 2834
Traded in other countries O7PA.Germany NBSE.USA
Address 700 Technology Drive, Pittsburgh, PA, USA, 15219
NeuBase Therapeutics Inc is pre-clinical stage bio-pharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.